Prophylactic effects of Bacille Calmette-Guérin intravesical instillation therapy: Time period-related comparison between Japan and Western countries

详细信息    查看全文

• 作者：Takehiko Okamura (1)
  Ryosuke Ando (1) (2)
  Hidetoshi Akita (1)
  Noriyasu Kawai (2)
  Keiichi Tozawa (2)
  Kenjiro Kohri (2)
  Hideo Arano (3)
  
• 关键词：Bacille Calmette ; Guérin (BCG) ; Intravesical instillation ; Non ; muscle invasive bladder cancer (NMIBC) ; Prophylactic use ; Time period ; related comparison
• 刊名：Current Urology Reports
• 出版年：2014
• 出版时间：January 2014
• 年：2014
• 卷：15
• 期：1
• 全文大小：361 KB
• 参考文献：1. Smith Jr JA, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol. 1999;162:1697-01. CrossRef
  2. Oosterlinck W, Lobel B, Jackse G, Malmstr?m PU, St?ckle M, Strenberg C; European Association of Urology. EAU Recommendations 2001. "Guidelines on bladder cancer", 2001.
  3. Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int. 2006;97:1199-01. CrossRef
  4. Sivalingam S, Probert JL, Schwaibold H. The role of repeat transurethral resection in the management of high-risk superficial transitional cell bladder cancer. BJU Int. 2005;96:759-2. CrossRef
  5. ?-Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol. 2012;186:2158-7. / This paper reports a review of most major current guidelines and emphasized the importance of re-TUR for the management of NMIBC.. CrossRef
  6. Tachibana M, Jitsukawa S, Iigaya T, Shibayama T, Baba S, Deguchi N, et al. Comparative study on prophylactic intravesical instillation of bacillus Calmette-Guerin (BCG) and adriamycin for superficial bladder cancers. Jpn J Urol. 1989;80:1459-5.
  7. Yamamoto T, Hagiwara M, Nakazono M, Yamamoto H. Intravesical bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder cancer. Prospective randomized study for prophylactic effect. Jpn J Urol. 1990;81:997-001.
  8. Yabusaki N, Komatsu H, Tago K, Yamada Y, Ueno A. Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin. Jpn J Urol. 1991;82:290-.
  9. Ozono S, Tabata S, Kaneko Y, Maruyama Y, Babaya K, Yamada K, et al. Outcomes of intravesical instillation of bacillus Calmette-Guerin (BCG) therapy for superficial bladder cancer. Ann Soc BCG BRM Imm. 1992;16:79-3.
  10. Ao T, Uchida T, Yokoyama E, Kawakami T, Adachi K, Mashimo S, et al. Prophylactic combination therapy after TUR of superficial bladder cancer. Acta Urol Jpn. 1993;39:987-1.
  11. Kano M, Kanemura M, Yokoyama M. Risk factor of tumor recurrence following intravesical instillation of bacillus Calmette-Guerin (BCG) therapy for superficial bladder cancer. Ann Soc BCG BRM Imm. 1993;17:39-4.
  12. Tachibana M, Nakamura S, Jitsukawa S, Deguchi N, Baba S, Hata M, et al. Long-term results and risk factors of tumor recurrence in patients with superficial bladder cancer who were treated by intravesical bacillus Calmette-Guerin (BCG) instillation. Jpn J Urol. 1993;84:656-1.
  13. Irie A, Lee KE, Kadowaki K, Sawamura M. Long-term results and complications of intravesical instillation of bacillus Calmette-Guerin for prophylaxis of bladder cancer recurrence. Acta Urol Jpn. 1994;40:873-.
  14. Tanaka T, Shinoda M, Maruyama T, Sasaki H, Naga H, Kuwahara Y, et al. The 25 cases of tumor recurrence after intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. Ann Soc BCG BRM Imm. 1994;18:95-00.
  15. Takashi M, Wakai K, Ohno Y, Murase T, Miyake K. Evaluation of a low-dose intravesical bacillus Calmette-Guérin (Tokyo strain) therapy for superficial bladder cancer. Int Urol and Nephrol. 1995;27:723-3. CrossRef
  16. Ao T, Uchida T, Muramoto M, Ito K, Masui N, Kawakami T, et al. Postoperative intravesical pirarubicin plus bacillus Calmette-Guérin with or without interleukin-2 instillation therapy for superficial bladder cancer. Nishinihon J Urol. 1996;5:538-1.
  17. Ozono S, Takashima K, Yoshida K, Hirao Y, Samma S, Okajima E. Intravesical bacillus Calmette-Guerin (BCG) therapy for prophylaxis of the superficial bladder cancer -Outcomes of randomized study-. Ann Soc BCG BRM Imm. 1997;21:87-1.
  18. Tozawa K, Okamura T, Yamada Y, Hayashi Y, Sasaki S, Kohri K. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer. Urol Int. 2001;67:289-2. CrossRef
  19. Irie A, Uchida T, Yamashita H, Matsumoto K, Satoh T, Koh H, et al. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence. Int J Urol. 2003;10:183-. CrossRef
  20. Hinotsu S, Akaza H, Isaka S, Kanetake H, Kubota Y, Kuroda M, et al. BCG Tokyo 172 Strain Study Group. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. Urology. 2006;67:545-. CrossRef
  21. Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, et al. Cancer Registration Committee of the Japanese Urological Association. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-001 report from the Japanese Urological Association. Int J Urol. 2009;16:279-6. CrossRef
  22. Segawa N, Inamoto T, Nomi H, Ibuki N, Azuma H, Katsuoka Y. Effect of prophylactic intravesical instillation of BCG for superficial bladder cancer. Acta Urol Jpn. 2009;55:175-0.
  23. Hinotsu S, Akaza H, Naito S, Ozono S, Sumiyoshi Y, Noguchi S, et al. Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscleinvasive bladder cancer. BJU Int. 2011;108:187-5. CrossRef
  24. Lamm DL. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol. 1985;134:40-.
  25. Herr HW, Pinsky CM, Whitmore Jr WF, Sogani PG, Oettgen HF, Melamed MR. Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors. Urology. 1985;25:119-3. CrossRef
  26. Badalament RA, Herr HW, Wong GY, Gnecco C, Pinsky CM, Whitmore Jr WF, et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol. 1987;5:441-.
  27. Martínez-Pi?eiro JA, Jiménez León J, Martínez-Pi?eiro Jr L, Fiter L, Mosteiro JA, Navarro J, et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990;143:502-.
  28. Lamm DL, DeHaven JI, Shriver J, Crispen R, Grau D, Sarosdy MF. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer. J Urol. 1990;144:65-.
  29. Jauhiainen KE, Alfthan OS. Instillation therapy in superficial urinary bladder cancer. Finnbladder Group. Scand J Urol Nephrol Suppl. 1991;138:179-5.
  30. D'Ancona CA, Netto Júnior NR, Claro JA, Ikari O. Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma. J Urol. 1991;145:498-01.
  31. Witjes JA, Fransen MP, van der Meijden AP, Doesburg WH, Debruyne FM. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study. Urol Int. 1993;51:67-2. CrossRef
  32. Lamm DL, Riggs DR, Shriver JS, van Gilder PF, Rach JF, DeHaven JI. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol. 1994;151:21-.
  33. Kamat MR, Kulkarni JN, Tongaonkar HB, Dalal AV. Intravesical bacillus Calmette-Guerin for superficial bladder cancer: experience with Danish 1331 strain. J Urol. 1994;152:1424-.
  34. Vegt PD, Witjes JA, Witjes WP, Doesburg WH, Debruyne FM, van der Meijden AP. A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol. 1995;153:929-3. CrossRef
  35. Lamm DL, Blumenstein BA, David Crawford E, Crissman JD, Lowe BA, Smith Jr JA, et al. Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol. 1995;1:119-6. CrossRef
  36. Lüftenegger W, Ackermann DK, Futterlieb A, Kraft R, Minder CE, Nadelhaft P, et al. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol. 1996;155:483-. CrossRef
  37. Krege S, Giani G, Meyer R, Otto T, Rübben H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. J Urol. 1996;156:962-. CrossRef
  38. Gruenwald IE, Stein A, Rashcovitsky R, Shifroni G, Lurie A. A 12 versus 6-week course of bacillus Calmette-Guerin prophylaxis for the treatment of high risk superficial bladder cancer. J Urol. 1997;157:487-1. CrossRef
  39. Yal?inkaya F, Kami? L, Ozteke O, Günlüsoy B, Yigitba?i O, Unal S. Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer. Int Urol Nephrol. 1998;30:41-. CrossRef
  40. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlén BJ. 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol. 1999;161:1124-. CrossRef
  41. Ali-El-Dein B, Nabeeh A, Ismail EH, Ghoneim MA. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study. J Urol. 1999;162:339-2. CrossRef
  42. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder cancer: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124-. CrossRef
  43. Palou J, Laguna P, Millán-Rodríguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodríguez J. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol. 2001;165:1488-1. CrossRef
  44. Martínez-Pi?eiro JA, Flores N, Isorna S, Solsona E, Sebastián JL, Pertusa C, et al. for CUETO (Club Urológico Espa?ol de Tratamiento Oncológico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int. 2002;89:671-0. CrossRef
  45. Librenjak D, Situm M, Eterovic D, Dogas Z, Gotovac J. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer. Croat Med J. 2003;44:187-2.
  46. Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY, et al. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer. Int J Urol. 2005;12:449-5. CrossRef
  47. Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006;176:935-. CrossRef
  48. Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol. 2007;52:1123-. CrossRef
  49. Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, et al. CUETO Group (Club Urológico Espa?ol De Tratamiento Oncológico). A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol. 2007;52:1398-06. CrossRef
  50. Duchek M, Johansson R, Jahnson S, Mestad O, Hellstr?m P, Hellsten S, et al. Members of the Urothelial Cancer Group of the Nordic Association of Urology. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol. 2010;57:25-1. CrossRef
  51. ?-Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57:766-3. / This reference emphasized the superior efficacy of maintenance BCG therapy, comparing anti-cancer drug even in intermediate risk group.. CrossRef
  52. Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, et al. Mototsugu Oya and Tsuneharu Miki, the Cancer Registration Committee of the Japanese Urological Association Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-001 report from the Japanese Urological Association. Int J Urol. 2009;16:279-6. CrossRef
  53. Yoneyama T, Ohyama C, Imai A, Ishimura H, Hagisawa S, Iwabuchi I, et al. Low-dose instillation therapy with bacille Calmette-Guérin Tokyo 172 strain after transurethral resection: historical cohort study. Urology. 2008;71:1161-. CrossRef
  54. Martínez-Pi?eiro JA, Martínez-Pi?eiro L, Solsona E, Rodríguez RH, Gómez JM, Martín MG, et al. Club Urológico Espa?ol de Tratamiento Oncológico (CUETO). Has a 3-fold decreased dose of Bacillus Calmette-Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol. 2005;174:1242-. CrossRef
  55. Sylvester RJ. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer. Int J Urol. 2011;18:113-0. CrossRef
  56. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pi?eiro L, Gonzalez M, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182:2195-03. CrossRef
  57. Joudi FN, Smith BJ, O’Donnell MA, Konety BR. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol. 2006;175:1634-0. CrossRef
  58. Kohjimoto Y, Iba A, Shintani Y, Inagaki T, Uekado Y, Hara I. Impact of patient age on outcome following bladder-preserving treatment for non-muscle-invasive bladder cancer. World J Urol. 2010;28:425-0. CrossRef
  59. Okamura T, Akita H, Hashimoto Y, Tozawa K, Hinotsu S, Akaza H, et al. Non Muscle Invasive Bladder Cancer Cases Initially Failing to Respond to Bacillus Calmette-Guérin Intravesical Instillation Therapy. Curr Urol. 2010;4:18-4. CrossRef
  60. ?-Margel D, Alkhateeb SS, Finelli A, Fleshner N. Diminished efficacy of Bacille Calmette-Guérin among elderly patients with nonmuscle invasive bladder cancer. Urology. 2011;78:848-5. / This study demonstrated the accurate diminished efficacy of BCG among elderly patients rather than younger ones.. CrossRef
  
• 作者单位：Takehiko Okamura (1)
  Ryosuke Ando (1) (2)
  Hidetoshi Akita (1)
  Noriyasu Kawai (2)
  Keiichi Tozawa (2)
  Kenjiro Kohri (2)
  Hideo Arano (3)
  
  1. Department of Urology, J.A. Aichi Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, 446-8602, Japan
  2. Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  3. Product Information Department, Japan BCG Laboratory, Tokyo, Japan
  
• ISSN：1534-6285

文摘

Guidelines change every few years regarding the prophylactic use of Bacille Calmette-Guérin (BCG) against non-muscle invasive bladder cancer. We performed a retrospective comparison to clarify the differences in BCG efficacy, based on time period, between Japan and Western countries . Published literature on 18 Japanese and 28 Western patient studies were compared to evaluate differences in BCG efficacy. Additionally, Internet searches were performed to obtain comparative Japanese and Western data. BCG efficacy in Japanese literature tended to show decreasing non-recurrence rates by time period. Non-recurrence rates in Western countries increased each year. This discrepancy may stem from a number of factors, including changes in accepted BCG indications, the introduction of restaging transurethral resection (re-TUR), the concept of BCG maintenance, and the evolution of histopathological diagnostic criteria.